These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 19118044)
1. Characterization of genetically modified T-cell receptors that recognize the CEA:691-699 peptide in the context of HLA-A2.1 on human colorectal cancer cells. Parkhurst MR; Joo J; Riley JP; Yu Z; Li Y; Robbins PF; Rosenberg SA Clin Cancer Res; 2009 Jan; 15(1):169-80. PubMed ID: 19118044 [TBL] [Abstract][Full Text] [Related]
2. Therapy of established tumors in a novel murine model transgenic for human carcinoembryonic antigen and HLA-A2 with a combination of anti-idiotype vaccine and CTL peptides of carcinoembryonic antigen. Saha A; Chatterjee SK; Foon KA; Celis E; Bhattacharya-Chatterjee M Cancer Res; 2007 Mar; 67(6):2881-92. PubMed ID: 17363612 [TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the carcinoembryonic antigen derived peptide 694 in HLA-A2 healthy donors and colorectal carcinoma patients. Alves PM; Viatte S; Fagerberg T; Michielin O; Bricard G; Bouzourene H; Vuilleumier H; Kruger T; Givel JC; Lévy F; Speiser DE; Cerottini JC; Romero P Cancer Immunol Immunother; 2007 Nov; 56(11):1795-805. PubMed ID: 17447064 [TBL] [Abstract][Full Text] [Related]
4. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Zaremba S; Barzaga E; Zhu M; Soares N; Tsang KY; Schlom J Cancer Res; 1997 Oct; 57(20):4570-7. PubMed ID: 9377571 [TBL] [Abstract][Full Text] [Related]
5. Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions. Robbins PF; Li YF; El-Gamil M; Zhao Y; Wargo JA; Zheng Z; Xu H; Morgan RA; Feldman SA; Johnson LA; Bennett AD; Dunn SM; Mahon TM; Jakobsen BK; Rosenberg SA J Immunol; 2008 May; 180(9):6116-31. PubMed ID: 18424733 [TBL] [Abstract][Full Text] [Related]
6. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. Tsang KY; Zaremba S; Nieroda CA; Zhu MZ; Hamilton JM; Schlom J J Natl Cancer Inst; 1995 Jul; 87(13):982-90. PubMed ID: 7629885 [TBL] [Abstract][Full Text] [Related]
7. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes. Duong MN; Erdes E; Hebeisen M; Rufer N J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351 [TBL] [Abstract][Full Text] [Related]
8. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. Wu Y; Wan T; Zhou X; Wang B; Yang F; Li N; Chen G; Dai S; Liu S; Zhang M; Cao X Cancer Res; 2005 Jun; 65(11):4947-54. PubMed ID: 15930317 [TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1 Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742 [TBL] [Abstract][Full Text] [Related]
10. Dendritic cells pulsed with CEA peptide induce CEA-specific CTL with restricted TCR repertoire. Alters SE; Gadea JR; Sorich M; O'Donoghue G; Talib S; Philip R J Immunother; 1998 Jan; 21(1):17-26. PubMed ID: 9456432 [TBL] [Abstract][Full Text] [Related]
11. Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells. Ohta K; Yamaguchi Y; Shimizu K; Miyahara E; Toge T Anticancer Res; 2002; 22(5):2597-606. PubMed ID: 12529970 [TBL] [Abstract][Full Text] [Related]
12. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase. Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771 [TBL] [Abstract][Full Text] [Related]
13. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047 [TBL] [Abstract][Full Text] [Related]
14. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T. Erickson TA; Shih YP; Fass J; Jang M; Tran E Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601 [No Abstract] [Full Text] [Related]
15. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Knutson KL; Disis ML Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190 [TBL] [Abstract][Full Text] [Related]
16. Avidity characterization of genetically engineered T-cells with novel and established approaches. Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667 [TBL] [Abstract][Full Text] [Related]
17. Defining virus-specific CD8+ TCR repertoires for therapeutic regeneration of T cells against chronic hepatitis E. Soon CF; Behrendt P; Todt D; Manns MP; Wedemeyer H; Sällberg Chen M; Cornberg M J Hepatol; 2019 Oct; 71(4):673-684. PubMed ID: 31203151 [TBL] [Abstract][Full Text] [Related]
18. Identification of NY-ESO-1 Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF Front Immunol; 2021; 12():644520. PubMed ID: 33833762 [TBL] [Abstract][Full Text] [Related]